141 related articles for article (PubMed ID: 19625388)
1. The effects of acute tryptophan depletion on mood in patients with Parkinson's disease and the healthy elderly.
Mace JL; Porter RJ; Dalrymple-Alford JC; Anderson TJ
J Psychopharmacol; 2010 Apr; 24(4):615-9. PubMed ID: 19625388
[TBL] [Abstract][Full Text] [Related]
2. Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson's disease.
Mace JL; Porter RJ; Dalrymple-Alford JC; Wesnes KA; Anderson TJ
J Psychopharmacol; 2010 Oct; 24(10):1465-72. PubMed ID: 19460872
[TBL] [Abstract][Full Text] [Related]
3. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease.
Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF
J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999
[TBL] [Abstract][Full Text] [Related]
4. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.
Riedel O; Heuser I; Klotsche J; Dodel R; Wittchen HU;
J Geriatr Psychiatry Neurol; 2010 Mar; 23(1):27-34. PubMed ID: 20042544
[TBL] [Abstract][Full Text] [Related]
5. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
[TBL] [Abstract][Full Text] [Related]
6. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach.
Leentjens AF; Scholtissen B; Vreeling FW; Verhey FR
Neuropsychopharmacology; 2006 May; 31(5):1009-15. PubMed ID: 16205779
[TBL] [Abstract][Full Text] [Related]
7. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF
Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473
[TBL] [Abstract][Full Text] [Related]
8. Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
Pålhagen SE; Carlsson M; Curman E; Wålinder J; Granérus AK
Acta Neurol Scand; 2008 May; 117(5):295-304. PubMed ID: 18279483
[TBL] [Abstract][Full Text] [Related]
9. The effects of acute tryptophan depletion on neuropsychological function, mood and movement in the healthy elderly.
Mace JL; Porter RJ; Dalrymple-Alford JC; Wesnes KA; Anderson TJ
J Psychopharmacol; 2011 Oct; 25(10):1337-43. PubMed ID: 21262857
[TBL] [Abstract][Full Text] [Related]
10. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
11. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease.
Ehrt U; Brønnick K; Leentjens AF; Larsen JP; Aarsland D
Int J Geriatr Psychiatry; 2006 Mar; 21(3):252-8. PubMed ID: 16477585
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
Jagannathan V; Venitz J
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the effect of acute tryptophan depletion on declarative episodic memory: a pooled analysis of nine studies.
Sambeth A; Blokland A; Harmer CJ; Kilkens TO; Nathan PJ; Porter RJ; Schmitt JA; Scholtissen B; Sobczak S; Young AH; Riedel WJ
Neurosci Biobehav Rev; 2007; 31(4):516-29. PubMed ID: 17229463
[TBL] [Abstract][Full Text] [Related]
14. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Devos D; Dujardin K; Poirot I; Moreau C; Cottencin O; Thomas P; Destée A; Bordet R; Defebvre L
Mov Disord; 2008 Apr; 23(6):850-7. PubMed ID: 18311826
[TBL] [Abstract][Full Text] [Related]
15. Affect in Parkinson's disease: validation of the two-factor approach.
Pourcher E; Rémillard S; Cohen H
J Neurol Sci; 2010 Feb; 289(1-2):27-31. PubMed ID: 19747694
[TBL] [Abstract][Full Text] [Related]
16. Apathy and depression in Parkinson disease.
Oguru M; Tachibana H; Toda K; Okuda B; Oka N
J Geriatr Psychiatry Neurol; 2010 Mar; 23(1):35-41. PubMed ID: 20015839
[TBL] [Abstract][Full Text] [Related]
17. The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients.
Booij L; Van der Does AJ; Haffmans PM; Riedel WJ; Fekkes D; Blom MJ
J Psychopharmacol; 2005 May; 19(3):267-75. PubMed ID: 15888512
[TBL] [Abstract][Full Text] [Related]
18. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and serotonergic vulnerability to depression: convergent findings.
Booij L; Van der Does AJ
J Abnorm Psychol; 2007 Feb; 116(1):86-94. PubMed ID: 17324019
[TBL] [Abstract][Full Text] [Related]
20. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
